Dexmedetomidine / Ketamine / Lidocaine for Temporomandibular Joint Disorder (TMJ Disorder)

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Temporomandibular Joint Disorder (TMJ Disorder)Dexmedetomidine / Ketamine / Lidocaine - Drug
Eligibility
18 - 75
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether patients who have surgery on their temporomandibular joint (TMJ) recover better when they do not receive opioids during anesthesia.

Eligible Conditions
  • Temporomandibular Joint Disorder (TMJ Disorder)

Treatment Effectiveness

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: 48 hours postoperatively

48 hours postoperatively
Incidence of Opioid Related Adverse Effects
Percocet Use
Perioperative Opioid Use
Day 1
Length of Stay
Pain Satisfaction
Pain Score
Rescue Analgesia in the PACU

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Standard Anesthesia
1 of 2
Opioid-free Anesthesia
1 of 2

Active Control

Experimental Treatment

60 Total Participants · 2 Treatment Groups

Primary Treatment: Dexmedetomidine / Ketamine / Lidocaine · No Placebo Group · Phase 2

Opioid-free Anesthesia
Drug
Experimental Group · 1 Intervention: Dexmedetomidine / Ketamine / Lidocaine · Intervention Types: Drug
Standard AnesthesiaNoIntervention Group · 1 Intervention: Standard Anesthesia · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 48 hours postoperatively

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,703 Previous Clinical Trials
30,853,100 Total Patients Enrolled
Jingping Wang, MDPrincipal InvestigatorMassachusetts General Hospital

Eligibility Criteria

Age 18 - 75 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: